Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8666792 | 0.88 | P2RY12 (0.44) | P2RY1 | |
| SCHEMBL7516040 | 0.88 | P2RY12 (0.44) | P2RY1 | |
| SCHEMBL19519462 | 0.85 | ADA (0.50) | ENPP1POLBP2RY1ADORA1 | |
| SCHEMBL17283106 | 0.85 | ADA (0.50) | ENPP1POLBP2RY1ADORA1 | |
| SCHEMBL338780 | 0.85 | POLB (0.60) | P2RX3P2RX4P2RX2ABCB1GSK3A | |
| SCHEMBL19771220 | 0.84 | ADORA1 (0.47) | ENPP1STING1POLBP2RY1ADORA1 | |
| SCHEMBL19767622 | 0.84 | ADORA1 (0.47) | ENPP1STING1POLBP2RY1ADORA1 | |
| SCHEMBL19519465 | 0.84 | ADORA1 (0.49) | P2RX3P2RX4ENPP1POLBP2RY1 | |
| SCHEMBL17283108 | 0.84 | ADORA1 (0.49) | P2RX3P2RX4ENPP1POLBP2RY1 | |
| SCHEMBL532524 | 0.83 | P2RX3 (0.55) | P2RX3P2RX4P2RX2ABCB1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882059-B1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES | LYNX THERAPEUTICS INC (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-0882059-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3-'P5'- PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1998-12-09 | — | — | EP | disclosed |
| US-5824793-A | ACTIVATING A 3'-DEPROTECTED AMINONUCLEOSIDE-5-PHOSPHORAMIDITE WITH TETRAZOLE AND REACTING WITH A 3'-PROTECTED AMINONUCLEOSIDE-5-PHOSPHORAMIDITE; OXIDATION OF THE PHOSPHORUS; | LYNX THERAPEUTICS, INC. (US) | 1998-10-20 | — | — | US | disclosed |
| WO-1997031009-A1 | SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES | LYNX THERAPEUTICS, INC. (US) | 1997-08-28 | — | — | WO | disclosed |